Physician profile
Barbara E Shortle
NPI 1699800466
$1,860.84
in general payments reported to CMS, 2019-2025
13 companies · $16.96 in 2025
The $16.96 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $391 · 2020: $89.71 · 2021: $378 · 2022: $796 · 2023: $155 · 2024: $33.93 · 2025: $16.96.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $206.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $619.01 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $600.69 | 2019-2023 | Rexulti |
| Alkermes, INC. | $195.22 | 2022-2023 | Lybalvi, Aristada |
| Duchesnay USA Incorporated | $117.81 | 2019 | |
| Sunovion Pharmaceuticals INC. | $67.24 | 2020-2021 | |
| Therapeuticsmd, INC. | $64.62 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $33.95 | 2019 | |
| Lilly USA, LLC | $33.93 | 2024 | Zepbound |
| Clovis Oncology, INC. | $33.45 | 2019 | |
| Scynexis, INC. | $32.11 | 2021 | |
| Hologic Sales and Service, LLC | $30.54 | 2020 | |
| Intra-Sana Laboratories | $16.96 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Currax Pharmaceuticals LLC | $15.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Shortle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.